Literature DB >> 19760239

Retrospective analysis of patients for development of nephrogenic systemic fibrosis following conventional angiography using gadolinium-based contrast agents.

Hanno Hoppe1, Sara Spagnuolo, Johannes M Froehlich, Helga Nievergelt, Hans-Peter Dinkel, Silvia Gretener, Harriet C Thoeny.   

Abstract

PURPOSE: The purpose was to retrospectively review the data of 27 patients with renal insufficiency who underwent conventional angiography with gadolinium-based contrast agents (GDBCA) as alternative contrast agents and assess the occurrence of nephrogenic systemic fibrosis (NSF) together with associated potential risk factors.
METHODS: This HIPAA-compliant study had institutional review board approval, and informed consent was waived. Statistical analysis was performed for all available laboratory and clinical data, including dermatology reports. Type and amount of the GDBCA used were recorded for angiography and additional MRI studies, if applicable. Serum creatinine levels (SCr) pre- and post-angiography were recorded, and estimated glomerular filtration rates (eGFR) were calculated.
RESULTS: Ten female and 17 male patients who underwent angiography with GDBCA were included. The mean amount of GDBCA administered was 44 +/- 15.5 ml (range 15-60 ml) or 0.24 + 0.12 mmol/kg (range 0.1-0.53 mmol/kg). At the time of angiography all patients had renal insufficiency (eGFR <60 ml/min/1.73 m(2)). Mean eGFR pre-angiography was 26 ml/min/1.73 m(2) and 33 ml/min/1.73 m(2) post-angiography. The mean follow-up period covers 28 months, range 1-84 months. Additional MRI studies with GDBCA administration were performed in 15 patients. One patient with typical skin lesions had developed biopsy-confirmed NSF.
CONCLUSION: Conventional arterial angiography with GDBCA may play a role in the development of NSF in patients with renal insufficiency. Alternative contrast agents, such as CO(2) angiography or rather the use of low doses of iodinated contrast agents, should be considered in these patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19760239     DOI: 10.1007/s00330-009-1586-0

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  22 in total

1.  Gadolinium--a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?

Authors:  Thomas Grobner
Journal:  Nephrol Dial Transplant       Date:  2006-01-23       Impact factor: 5.992

2.  Safety of CO(2)- and gadodiamide-enhanced angiography for the evaluation and percutaneous treatment of renal artery stenosis in patients with chronic renal insufficiency.

Authors:  D J Spinosa; A H Matsumoto; J F Angle; K D Hagspiel; D Cage; E A Bissonette; K G Koenig; C R Ayers; K McConnell
Journal:  AJR Am J Roentgenol       Date:  2001-05       Impact factor: 3.959

3.  Nephrogenic systemic fibrosis: the nosological and conceptual evolution of nephrogenic fibrosing dermopathy.

Authors:  Shawn E Cowper
Journal:  Am J Kidney Dis       Date:  2005-10       Impact factor: 8.860

4.  Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis.

Authors:  Whitney A High; Reed A Ayers; John Chandler; Gary Zito; Shawn E Cowper
Journal:  J Am Acad Dermatol       Date:  2006-11-09       Impact factor: 11.527

5.  Long-term retention of gadolinium in tissues from nephrogenic systemic fibrosis patient after multiple gadolinium-enhanced MRI scans: case report and implications.

Authors:  Charu Thakral; Jihad Alhariri; Jerrold L Abraham
Journal:  Contrast Media Mol Imaging       Date:  2007-07       Impact factor: 3.161

6.  Safety of gadolinium contrast angiography in patients with chronic renal insufficiency.

Authors:  Albert D Sam; Mark D Morasch; Jeremy Collins; Gina Song; Richard Chen; F Scott Pereles
Journal:  J Vasc Surg       Date:  2003-08       Impact factor: 4.268

7.  Gadolinium-enhanced MR imaging and nephrogenic systemic fibrosis: retrospective study of a renal replacement therapy cohort.

Authors:  Tara Anne Collidge; Peter Campbell Thomson; Patrick Barry Mark; James Phillip Traynor; Alan George Jardine; Scott Thomas William Morris; Keith Simpson; Giles Hannibal Roditi
Journal:  Radiology       Date:  2007-08-17       Impact factor: 11.105

8.  Prevalence of nephrogenic systemic fibrosis in renal insufficiency patients: results of the FINEST study.

Authors:  Nicolas Janus; Vincent Launay-Vacher; Svetlana Karie; Olivier Clement; Elena Ledneva; Camille Frances; Gabriel Choukroun; Gilbert Deray
Journal:  Eur J Radiol       Date:  2009-01-06       Impact factor: 3.528

Review 9.  Nephrogenic systemic fibrosis associated with gadolinium based contrast agents: a summary of the medical literature reporting.

Authors:  Dale R Broome
Journal:  Eur J Radiol       Date:  2008-03-26       Impact factor: 3.528

10.  ESUR guideline: gadolinium-based contrast media and nephrogenic systemic fibrosis.

Authors:  Henrik S Thomsen
Journal:  Eur Radiol       Date:  2007-10       Impact factor: 7.034

View more
  8 in total

Review 1.  [Combined use of contrast media containing iodine and gadolinium for imaging and intervention : A hitherto widely ignored topic in radiological practice].

Authors:  W Golder
Journal:  Radiologe       Date:  2012-02       Impact factor: 0.635

Review 2.  Recent hot topics in contrast media.

Authors:  Henrik S Thomsen
Journal:  Eur Radiol       Date:  2010-12-07       Impact factor: 5.315

3.  Unenhanced calf MR angiography at 3.0 T using electrocardiography-gated partial-fourier fast spin echo imaging with variable flip angle.

Authors:  Dan Li; Jiang Lin; Fuhua Yan; Qingyuan Wu; Weiwei Lv; Yan San; Hong Yun
Journal:  Eur Radiol       Date:  2010-12-14       Impact factor: 5.315

4.  Risk for Nephrogenic Systemic Fibrosis After Exposure to Newer Gadolinium Agents: A Systematic Review.

Authors:  Joseph Lunyera; Dinushika Mohottige; Anastasia-Stefania Alexopoulos; Hilary Campbell; C Blake Cameron; Nicole Sagalla; Timothy J Amrhein; Matthew J Crowley; Jessica R Dietch; Adelaide M Gordon; Andrzej S Kosinski; Sarah Cantrell; John W Williams; Jennifer M Gierisch; Belinda Ear; Karen M Goldstein
Journal:  Ann Intern Med       Date:  2020-06-23       Impact factor: 25.391

5.  Iodine contrast iso-attenuating with diagnostic gadolinium doses in CTA and angiography results in ultra-low iodine doses. A way to avoid both CIN and NSF in azotemic patients?

Authors:  Ulf Nyman; Barbara Elmståhl; Håkan Geijer; Peter Leander; Torsten Almén; Mats Nilsson
Journal:  Eur Radiol       Date:  2010-08-29       Impact factor: 5.315

6.  Nephrogenic systemic fibrosis: review of 408 biopsy-confirmed cases.

Authors:  Zhitong Zou; Lin Ma
Journal:  Indian J Dermatol       Date:  2011-01       Impact factor: 1.494

7.  An Updated Study to Determine Association between Gadolinium-Based Contrast Agents and Nephrogenic Systemic Fibrosis.

Authors:  Bin Zhang; Long Liang; Wenbo Chen; Changhong Liang; Shuixing Zhang
Journal:  PLoS One       Date:  2015-06-15       Impact factor: 3.240

8.  Nephrogenic systemic fibrosis in Denmark--a nationwide investigation.

Authors:  Tina R Elmholdt; Anne B B Olesen; Bettina Jørgensen; Stinne Kvist; Lone Skov; Henrik S Thomsen; Peter Marckmann; Michael Pedersen
Journal:  PLoS One       Date:  2013-12-09       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.